Loading exclusive…
$ALT: Q2 Results Posted; MASH/AUD Pipeline Update Drives Post-Print Setup
Altimmune beats EPS estimates; focus shifts to MASH trial data and cash runway ahead of catalysts.
Key Points
- Q2 EPS of ($0.12) beats consensus of ($0.15).
- MASH Phase 3 data readout remains the primary near-term catalyst.
- Cash runway sufficient to fund operations through key milestones.
- AUD program advances but remains secondary to MASH timeline.
What To Watch
- MASH Phase 3 trial timeline and data readout announcement.
- Any updates on partnership discussions or licensing deals.
- Cash burn rate and potential capital raise announcements.
- Peer performance in NASH/AUD therapeutic space.